GlobeNewswire Inc | Sep 8, 2020 08:00AM EDT

September 08, 2020

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc.(Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a webcasted company overview at two upcoming investor conferences in September.

-- H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 a.m. ET -- Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 9:20 a.m. ET

A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone OncologyGritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillarssecond, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patients tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients TSNA to potentially drive the patients immune system to specifically attack and destroy tumors. The companys individualized neoantigen-based immunotherapy, GRANITE, and its off the shelf shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstones BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

ContactsMedia: Dan Budwick 1AB (973) 271-6085dan@1abmedia.com

Investors: Alexandra Santos Wheelhouse Life Science Advisors (510) 871-6161asantos@wheelhouselsa.com